Disease · MONDO_0044917
T-lymphoblastic lymphoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. T-lymphoblastic lymphoma. Diseases, record MONDO_0044917. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044917
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Precur. T-lymphoblastic lymphoma, precursor T Lymphoblastic lymphoma, precursor T-cell Lymphoblastic lymphoma
- Open Targets
Drugs39
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| MERCAPTOPURINE | CHEMBL1200751 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 4 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CYTARABINE | CHEMBL803 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| NELARABINE | CHEMBL1201112 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 39
See all 39 drugsTargets105
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 7 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 2 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/952 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5425 | Drugs and targets |
| POLD3 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/10714 | Drugs and targets |
| POLD4 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/57804 | Drugs and targets |
| POLE | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5426 | Drugs and targets |
1 to 10 of 105
See all 105 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02999633 | Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia | Phase 2 | 14 | 2020-01-18 | T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia | ISATUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | Phase 2 | 12 | 2023-10-31 | T-Acute Lymphoblastic Leukemia, Adult T Lymphoblastic Lymphoma | MOTIXAFORTIDE, NELARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT07072585 | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | Phase 2/3 | 1,708 | Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | BORTEZOMIB, CALASPARGASE PEGOL, CYCLOPHOSPHAMIDE, CYTARABINE, DARATUMUMAB, DAUNORUBICIN HYDROCHLORIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, HYDROCORTISONE, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PEGASPARGASE, PREDNISOLONE, PREDNISONE, THIOGUANINE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Phase 2/3 | 790 | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | BLINATUMOMAB, BORTEZOMIB, CALASPARGASE PEGOL, CLOFARABINE, CRISANTASPASE, CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, IDARUBICIN, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PEGASPARGASE, PREDNISONE, RUXOLITINIB, VINCRISTINE, VORINOSTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT05681260 | Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) | Phase 3 | 200 | T-cell Lymphoblastic Lymphoma | ASPARAGINASE, BORTEZOMIB, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, IFOSFAMIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE, VINDESINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06434467 | The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma | Phase 3 | 83 | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | NELARABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | Phase 2/3 | 80 | Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma, Leukemia, Lymphoblastic, Leukemia, T Cell, Adult Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoblastic Leukemia | CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, IDARUBICIN, METHOTREXATE, PEGASPARGASE, TUCIDINOSTAT, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02396043 | Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma | Phase 2 | 50 | Lymphoma, Lymphoblastic | MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PIRARUBICIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | Phase 2 | 30 | T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma, Refractory Leukemia, Safety, Efficacy, Self | IDARUBICIN, IFOSFAMIDE, METHOTREXATE, MITOXANTRONE, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT00199030 | Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath | Phase 2 | 8 | Adult Acute Lymphocytic Leukemia T-cell, Lymphoma, Lymphoblastic | ALEMTUZUMAB, CLADRIBINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials22
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044917
GET https://conductscience.org/api/diseases/v1/MONDO_0044917/drugs?page=2